# Medical Director, Clinical Development at Olema Oncology > Remote · United States · Director+ · Other · open. Source: https://alderhq.app/jobs/greenhouse%3Aolema%3A6211586004 (read 2026-11-13). ## Facts (observed) - Company: [Olema Oncology](https://alderhq.app/companies/olema-oncology) - Location text: Boston, Massachusetts; Remote; Rogers / Boston - Where it can be done from (inferred): Remote · United States (evidence: "Remote role open worldwide") - Posted: 2026-10-02 (42 days ago) - First seen by alder: 2026-11-07 · last verified: 2026-11-07 - Reposted: 0 times · edited: 0 times - Apply on the employer's site: https://job-boards.greenhouse.io/olema/jobs/6211586004 ## Pay and sponsorship - Posted pay: not posted - Market band for similar posted roles (Boston, n 366): p25 $190k, median $221k, p75 $263k ## Description (the employer's text) Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema. Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP-3136 in combination with Bayer’s darolutamide in metastatic castration-resistant prostate cancer by the end of this year. Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self-starters who bring consistency in our quest for the extraordinary every single day. If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond. About the Role \>\>\> Medical Director, Clinical Development As the Medical Director, you will serve as an Oncology Physician for palazestrant and play a pivotal role in advancing Olema’s late and early-stage clinical pipeline in breast cancer. You will contribute to registration-enabling studies by shaping study design, evaluating clinical data, and engaging with regulatory authorities, investigators, and key opinion leaders. Partnering closely with experienced physicians and cross-functional teams, you will ensure scientific rigor, data integrity, and patient-centric decision-making while contributing to biomarker development, publication planning, and external scientific communications. This is a unique opportunity to contribute at a pivotal moment in the program’s trajectory and support the advancement of therapies for patients with ER-positive, HER2-negative breast cancer. This role will be based in Cambridge, MA and may require up to 20% travel. Key Responsibilities Provide Medical Leadership and Expertise - Contribute to registration-enabling studies for palazestrant in combination with other therapies, including study design, regulatory engagement, and investigator collaboration - Partner across functions to define and implement clinical development strategies and plans for multiple programs - Serve as the medical expert and point of contact for clinical and scientific questions across internal and external stakeholders --- Data: alder (https://alderhq.app). Cite https://alderhq.app/jobs/greenhouse%3Aolema%3A6211586004 and the date you read it. Observed facts come from the employer's own listing; location reach, level, family and skills are inferences.